Lilly Rebuts Lexapro Onset To Efficacy Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Study finds Lilly's Cymbalta acts as rapidly as the Forest SSRI.
You may also be interested in...
Forest Credits Lexapro Growth To Less Detailing By Competitors
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
Forest Credits Lexapro Growth To Less Detailing By Competitors
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.